AMENDMENT TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings of claims in the application:

Listing of Claims:

1-31. (canceled)

32. (currently amended) A method for treating or managing a metalloproteinase (MMP) or calpain related disease or disorder_in a mammal, the disease or disorder being selected from the group consisting of cancer metastatis and glioma comprising administering to a mammal in need thereof, a pharmaceutical composition comprising a therapeutically effective amount of a compound of the Formula (I):

wherein

R is saturated or unsaturated alkyl, cycloalkyl, arylalkyl or cycloalkyl-alkyl radical having from 1 to 28 carbon atoms which may be interrupted by any combination of 1-6 oxygen and/or nitrogen atoms, provided that no two oxygen atoms or an oxygen and a nitrogen atom are directly connected to each other; and

M denotes a hydrogen or a physiologically acceptable cation.

33. (previously presented) The method according to claim 32, wherein said method further comprises treating the mammal with additional therapeutic treatment.

Application No. 10/529,028 Amendment dated May 13, 2010 Reply to Office Action of February 18, 2010

- 34. (previously presented) The method according to claim 32, wherein said mammal is a human.
- 35 to 37. (cancelled)
- 38. (previously presented) The method according to claim 32, wherein R in the compound of Formula (I) is a <u>phenylakyl</u> phenylakyl, and alky interrupted by zero to three oxygen atoms, or a monoalkyl ether of mono-, di-, or tri-ethylene glycol.
- 39. (previously presented) The method according to claim 32, wherein R in the compound of Formula (I) is selected from the group consisting of: C₈H₁₇, C₈H₁₇OCH₂CH₂, C₁₈H₃₇, C₁₈H₃₇OCH₂CH₂, benzyl-CH₂OCH₂CH₂, C₁₂H₂₅OCH₂CH₂, C₁₂H₂₅OCH₂CH₂)₃.
- 40. (previously presented) The method according to claim 32, wherein the metalloproteinase is MMP-9.
- 41 to 44. (cancelled)
- 45. (previously presented) The method according to claim 33, wherein said additional treatment is selected from the group consisting of chemotherapy, irradiation therapy, immunotherapy, genetic therapy and surgery.
- 46. (previously presented) The method according to claim 32, wherein said compound of Formula (I) is selected from the group consisting of:
- 1,2-bis(2-aminophenoxy)ethane, N,N'-di(2-octoxyethyl acetate),N, N'-diacetic acid;
- 1,2-bis(2-aminophenoxy)ethane, N, N'-di(2-octodecyloxyethyl acetate), N, N'-diacetic acid:
- 1,2-bis(2-aminophenoxy)ethane, N, N'-di(2-benzyloxyethyl acetate), N, N'-acetic acid;
- 1,2-bis(2-aminophenoxy)ethane, N, N'-di(2-dodecyloxyethyl acetate, N, N'-diacetic acid;
- 1,2-bis(2-aminophenoxy)ethane, N, N'-di[2-(2-dodecyloxyethoxy)-ethyl acetate], N, N'-diacetic acid; and

Application No. 10/529,028 Amendment dated May 13, 2010 Reply to Office Action of February 18, 2010

1,2-bis(2-aminophenoxy)ethane, N, N'-di $\{2[2-(2-dodecyloxyethoxy)ethoxy]-ethyl acetate\}$, N, N'-diacetic acid.

47. (cancelled)